Smith & Nephew (SN) Investor update summary
Event summary combining transcript, slides, and related documents.
Investor update summary
10 Jun, 2026Strategic growth, vision, and innovation priorities
Focus on four pillars—reach, innovate, scale, and execute efficiently—to drive 6%-7% organic revenue growth and 9%-13% trading profit growth over the next three years, targeting over $1 billion in free cash flow and 12%-13% ROIC by 2028.
RISE strategy emphasizes efficient execution, strategic investment, and expanding patient reach to improve margins and returns.
Robust product pipeline with increased launch cadence from 2026-2028 across orthopaedics, sports medicine, and wound management.
R&D investment is increasing, especially in sports medicine and wound care, with 44 products launched in the past three years and plans for 14-16 new launches annually through 2026.
Major scalable technology platforms include MTECH, TESSA, Lumos, and a rapidly evolving robotic platform.
Advanced wound management and innovation
Broad portfolio targets high-growth segments like pressure injury prevention, chronic wounds, and surgical site complications, with products such as LEAF, ALLEVYN COMPLETE CARE, and ALLEVYN Ag+ Surgical.
LEAF reduces pressure injury risk by 94%, while ALLEVYN COMPLETE CARE offers superior exudate management and flexibility.
PICO, a portable single-use negative pressure wound therapy device, reduces surgical site complications by up to 63% and length of stay by 1.75 days.
Over 200 patents and 310 studies, including 60 RCTs, support PICO's effectiveness; NICE recommends its use.
Continued investment in PICO aims to expand patient reach and accelerate innovation.
Sports medicine and biologics
REGENETEN bioinductive implant reduces rotator cuff re-tear rates by 65% at two years and is expanding to extra-articular ligaments.
CARTIHEAL AGILI-C implant provides twice the pain reduction of microfracture and reduces risk of knee replacement by over 80%, with durable 5-year outcomes.
TESSA introduces real-time, video-based navigation for arthroscopic surgery, enhancing ACL reconstruction accuracy and expanding future applications.
Tendon Seam offers stronger, more stable repairs, minimizing gap formation and supporting healing.
Latest events from Smith & Nephew
- Q1 2026 saw 3.1% underlying revenue growth and a $500m share buyback announcement.SN
Investor presentation27 May 2026 - Q1 2026 delivered 3.1% underlying growth, guidance reaffirmed, and a $500M buyback announced.SN
Q1 2026 TU12 May 2026 - Strong FY 2025 growth, margin expansion, and new strategy set stage for accelerated 2026 performance.SN
Investor presentation16 Mar 2026 - Strong FY2025 growth, margin expansion, and cash flow set up for accelerated 2026 performance.SN
Q4 20252 Mar 2026 - RISE strategy drives growth, innovation, and ASC leadership with strong financial targets for 2028.SN
CMD 20253 Feb 2026 - Q2 revenue up 5.6%, margin and cash flow improved, guidance and dividend maintained.SN
H1 20242 Feb 2026 - Q3 revenue up 4.0%, but China headwinds prompt lower 2024 margin and growth guidance.SN
Q3 2024 TU17 Jan 2026 - Strong growth, margin expansion, and cash flow improvement, with China as a key headwind.SN
H2 20247 Jan 2026 - Q1 2025 revenue grew 3.1% with innovation and margin guidance unchanged despite headwinds.SN
Q1 2025 TU21 Dec 2025